Haoyuan Pharma’s AI Drug Discovery Strategy Meets Its CDMO Platform
TMTPost reports that Haoyuan Pharma is using its compound inventory and synthesis capabilities to support AI-designed drug candidates through the ABC partnership with Insilico Medicine and Mabwell Biopharma, alongside its MedChemAI screening and customization platform. Haoyuan reported 182,000 molecules in reserve as of June 2026 and operates a Chongqing ADC CDMO facility that opened in March 2025. The report says no disclosed AI-related orders have yet demonstrated commercial demand for this model.
The profile connects AI-based payload and linker design with Haoyuan’s chemical synthesis and ADC manufacturing infrastructure, while also showing that the company has not disclosed commercial orders tied to the AI offerings.
（本文作者为 医曜，钛媒体经授权发布）
文 | 医曜
药物化学家的日常，大部分时间是失败的。
一个反应做三个月，走不通，推倒重来。换个条件，再做三个月。行内人有个自嘲的说法，叫“Chem is try”，化学就是试。
这门生意，就长在这句自嘲上。
上海有家公司叫皓元医药，二十年干的事，说白了就一句：把别人要试的东西，提前试好，摆上货架。
#Haoyuan Pharma#Insilico Medicine#Mabwell Biopharma#MedChemAI